Search

Displaying results 2121 - 2130 of 9132 in total
  1. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

    Synonyms: Fam-trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki
  2. Drug

    Eribulin

    go.drugbank.com/drugs/DB08871
    ApprovedInvestigational

    Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic

  3. Drug

    Disopyramide

    go.drugbank.com/drugs/DB00280
    ApprovedInvestigational

    A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar

  4. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.

  5. Drug

    Aliskiren

    go.drugbank.com/drugs/DB09026
    ApprovedInvestigational

    Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacio...

  6. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. … [L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria.

  7. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287]. … Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks

  8. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54106] Zemcelpro also contains [dorocubicel], a preparation CD34+ HSCs derived from the same cord blood sample and expanded _ex vivo_ using [UM-171]. … Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells are one component of Zemcelpro, a cryopreserved allogeneic hematopoietic stem and progenitor cell therapy.

  9. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

  10. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … [A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms.